Biotech Stocks To Watch Today – August 16th

Thermo Fisher Scientific, AbbVie, Danaher, Bloom Energy, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies engaged in developing, manufacturing or commercializing products based on biological processes—such as pharmaceuticals, gene therapies and diagnostic tools. Because these companies often invest heavily in research and face regulatory hurdles, their stock prices can be more volatile but also offer the potential for significant growth if clinical trials or regulatory approvals succeed. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of TMO stock traded up $4.92 during midday trading on Friday, hitting $489.96. 2,462,453 shares of the company were exchanged, compared to its average volume of 3,069,315. The firm has a market capitalization of $185.01 billion, a P/E ratio of 28.34, a PEG ratio of 2.59 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm’s 50 day moving average price is $434.83 and its two-hundred day moving average price is $460.79. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $627.88.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV stock traded up $1.97 during midday trading on Friday, hitting $206.65. 4,430,806 shares of the company were exchanged, compared to its average volume of 4,938,490. The firm has a market capitalization of $365.06 billion, a P/E ratio of 98.41, a PEG ratio of 1.32 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The firm’s 50 day moving average price is $191.08 and its two-hundred day moving average price is $192.08. AbbVie has a 52 week low of $163.81 and a 52 week high of $218.66.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Shares of DHR stock traded up $0.62 during midday trading on Friday, hitting $210.84. 3,210,213 shares of the company were exchanged, compared to its average volume of 4,658,279. The firm has a market capitalization of $150.97 billion, a P/E ratio of 44.86, a PEG ratio of 2.93 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm’s 50 day moving average price is $199.94 and its two-hundred day moving average price is $199.87. Danaher has a 52 week low of $171.00 and a 52 week high of $279.90.

Bloom Energy (BE)

Bloom Energy Corporation designs, manufactures, sells, and installs solid-oxide fuel cell systems for on-site power generation in the United States and internationally. The company offers Bloom Energy Server, a solid oxide technology that converts fuel, such as natural gas, biogas, hydrogen, or a blend of these fuels into electricity through an electrochemical process without combustion.

Shares of BE stock traded up $0.21 during midday trading on Friday, hitting $45.32. 12,427,549 shares of the company were exchanged, compared to its average volume of 12,190,416. The firm has a market capitalization of $10.60 billion, a P/E ratio of 1,133.28 and a beta of 3.28. The company has a debt-to-equity ratio of 2.18, a quick ratio of 3.21 and a current ratio of 4.99. The firm’s 50 day moving average price is $28.57 and its two-hundred day moving average price is $23.53. Bloom Energy has a 52 week low of $9.02 and a 52 week high of $47.21.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of VRTX stock traded up $2.49 during midday trading on Friday, hitting $392.79. 1,408,302 shares of the company were exchanged, compared to its average volume of 2,363,952. The firm has a market capitalization of $100.71 billion, a P/E ratio of 28.08 and a beta of 0.44. The firm’s 50 day moving average price is $444.95 and its two-hundred day moving average price is $463.78. Vertex Pharmaceuticals has a 52 week low of $362.50 and a 52 week high of $519.88.